| Recruiting | Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | Phase 3 | 2026-02-23 |
| Recruiting | Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design Fibromyalgia | Phase 3 | 2026-01-14 |
| Enrolling By Invitation | Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder Binge-Eating Disorder | Phase 3 | 2025-02-20 |
| Terminated | An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor | Phase 3 | 2024-11-21 |
| Recruiting | Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) Excessive Sleepiness, Shift-work Disorder | Phase 3 | 2024-08-01 |
| Recruiting | Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol Binge-Eating Disorder | Phase 3 | 2024-04-26 |
| Completed | Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol Major Depressive Disorder | Phase 3 | 2024-03-18 |
| Recruiting | A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Sympt Major Depressive Disorder | Phase 4 | 2023-12-27 |
| Completed | A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS) ADHD | Phase 3 | 2023-07-06 |
| Completed | A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation | Phase 3 | 2022-09-06 |
| Completed | Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to a Migraine | Phase 3 | 2022-08-31 |
| Completed | A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE Narcolepsy, Cataplexy, Excessive Daytime Sleepiness | Phase 3 | 2021-10-20 |
| Completed | A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy Narcolepsy, Cataplexy, Excessive Daytime Sleepiness | Phase 3 | 2021-09-15 |
| Completed | Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administr Narcolepsy, Obstructive Sleep Apnea, Excessive Daytime Somnolence | Phase 1 | 2021-08-27 |
| Completed | A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor | Phase 3 | 2021-06-17 |
| Completed | Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study Excessive Daytime Sleepiness, Obstructive Sleep Apnea, Impaired Cognitive Function | Phase 4 | 2021-05-17 |
| Unknown | An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients Major Depressive Disorder, Treatment Resistant Depression | Phase 2 | 2021-04-14 |
| Completed | Assessing Clinical Outcomes in Alzheimer's Disease Agitation Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor | Phase 3 | 2020-12-31 |
| Terminated | Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE) Treatment Resistant Depression, Major Depressive Disorder | Phase 2 | 2020-09-23 |
| Completed | Mechanistic Evaluation of Response in TRD (MERIT) Treatment Resistant Depression, Major Depressive Disorder | Phase 2 | 2020-08-13 |
| Completed | Initiating Early Control of Migraine Pain and Associated Symptoms Migraine | Phase 3 | 2019-10-08 |
| Recruiting | SUNOSI® (Solriamfetol) Pregnancy Registry Narcolepsy, Obstructive Sleep Apnea, Pregnant Women and Their Offspring | — | 2019-07-31 |
| Completed | Open-Label Safety Study of AXS-05 in Subjects With Depression Major Depressive Disorder, Treatment Resistant Depression, Depression | Phase 3 | 2019-07-08 |
| Completed | Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT) Migraine | Phase 3 | 2019-07-06 |
| Completed | A Trial of AXS-05 in Patients With Major Depressive Disorder Depression, Major Depressive Disorder | Phase 3 | 2019-06-20 |
| Completed | Maximizing Outcomes in Treating Acute Migraine Migraine | Phase 3 | 2019-03-04 |
| Completed | Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT) Narcolepsy, Cataplexy Narcolepsy, Excessive Sleepiness | Phase 2 | 2019-01-30 |
| Completed | Assessing Symptomatic Clinical Episodes in Depression Major Depressive Disorder | Phase 2 | 2018-05-30 |
| Completed | Addressing Dementia Via Agitation-Centered Evaluation Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor | Phase 2 / Phase 3 | 2017-07-13 |
| Unknown | A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow Lesio Osteoarthritis, Knee | Phase 3 | 2016-03-01 |
| Completed | A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Diso Treatment Resistant Major Depressive Disorder | Phase 3 | 2016-03-01 |
| Unknown | CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1 Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy | Phase 3 | 2015-07-01 |